PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell ...

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO ...

On May 8, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first trial site for the Phase 3 OVATION 3 trial has been activated and is ready to begin enrolling patients. During the quarterly ...

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the ... This investor event will include an expert panel of several leaders in hepatology ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement ...

Roche also announced that it would initiate a Phase 3 program for trontinemab, which is expected later this year. Results from 604 participants in a multicentre study of Roche’s Elecsys pTau181 ...

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes ...